Kiniksa Pharmaceuticals International, plc
KNSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001730430
In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Kiniksa Pharmaceuticals International, plc as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- +1 vs. Q2 2021
- Shares held
- 29.1M
- +3.62M (+14.2%) vs. Q2 2021
- Total value
- $332.0M
- −$23.5M (−6.6%) vs. Q2 2021
- New holders
- 20
- 37 more added
- Sold out
- 19
- 26 more reduced
2 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KNSA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 267 | $2.99B |
| Q1 2026 | 228 | $2.18B |
| Q4 2025 | 224 | $1.77B |
| Q3 2025 | 204 | $1.59B |
| Q2 2025 | 189 | $1.10B |
| Q1 2025 | 176 | $889.4M |
| Q4 2024 | 160 | $773.1M |
| Q3 2024 | 176 | $991.2M |
| Q2 2024 | 133 | $659.4M |
| Q1 2024 | 154 | $768.1M |
| Q4 2023 | 142 | $600.4M |
| Q3 2023 | 134 | $605.8M |
| Q2 2023 | 127 | $447.7M |
| Q1 2023 | 132 | $339.6M |
| Q4 2022 | 125 | $450.0M |
| Q3 2022 | 104 | $383.2M |
| Q2 2022 | 92 | $290.5M |
| Q1 2022 | 96 | $306.0M |
| Q4 2021 | 103 | $346.4M |
| Q3 2021 | 101 | $332.0M |
| Q2 2021 | 102 | $402.0M |
| Q1 2021 | 105 | $537.6M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Kiniksa Pharmaceuticals International, plc; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Pictet Asset Management SA | 3,334,905 | $38.0M | 0.04% | +3,334,905 | New |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −1,096,252−100.0% | Sold out |
| Logos Global Management LP | 0 | $0 | 0.00% | −800,000−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −400,296−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −72,300−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −49,232−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −47,178−100.0% | Sold out |
| Cetera Advisor Networks LLC | 0 | $0 | 0.00% | −43,632−100.0% | Sold out |
| AlphaCentric Advisors LLC | 0 | $0 | 0.00% | −32,500−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −28,744−100.0% | Sold out |
| Cerity Partners LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Parallax Volatility Advisers, L.P. | 0 | $0 | 0.00% | −16,586−100.0% | Sold out |
| Price T Rowe Associates Inc | 0 | $0 | 0.00% | −13,231−100.0% | Sold out |
| Cowen and Company, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| SG3 Management, LLC | 0 | $0 | 0.00% | −8,500−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −2,754−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −701−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −526−100.0% | Sold out |
| Beck Bode, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −235−100.0% | Sold out |
| Pictet Asset Management Ltd | – | – | – | – | Not filed |
| CWM, LLC | – | – | – | – | Not filed |